| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.0062 | 0.8 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | Roscovitine | GDSC1000 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.0084 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.0098 | 0.9 |